Canaccord Genuity Maintains Buy on BioNTech, Lowers Price Target to $136

Benzinga · 1d ago
Canaccord Genuity analyst John Newman maintains BioNTech (NASDAQ:BNTX) with a Buy and lowers the price target from $142 to $136.